Repligen Corp Annual Meeting Proxy Solicitation
Ticker: RGEN · Form: DEFA14A · Filed: Apr 4, 2025 · CIK: 730272
| Field | Detail |
|---|---|
| Company | Repligen Corp (RGEN) |
| Form Type | DEFA14A |
| Filed Date | Apr 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
Repligen proxy time! Vote on directors & auditors for May 15th meeting.
AI Summary
Repligen Corporation is holding its Annual Meeting and is soliciting proxies from shareholders. The company is asking shareholders to vote on various proposals, including the election of directors and the ratification of its independent registered public accounting firm. The meeting will be held virtually on May 15, 2025.
Why It Matters
Shareholders have the opportunity to influence the company's governance and strategic direction by voting on key proposals at the annual meeting.
Risk Assessment
Risk Level: low — This filing is a standard proxy statement for an annual meeting, not indicating any unusual risks.
Key Players & Entities
- REPLIGEN CORPORATION (company) — Registrant
- May 15, 2025 (date) — Annual Meeting Date
FAQ
What is the purpose of this DEFA14A filing?
This filing is a Definitive Additional Materials proxy statement from Repligen Corporation, soliciting votes from shareholders for its upcoming Annual Meeting.
When is Repligen Corporation's Annual Meeting scheduled to take place?
The Annual Meeting is scheduled to be held virtually on May 15, 2025.
What are the primary items shareholders will be voting on?
Shareholders will be voting on proposals including the election of directors and the ratification of the independent registered public accounting firm.
Where is Repligen Corporation headquartered?
Repligen Corporation is headquartered at 41 Seyon Street, Building 1, Suite 100, Waltham, MA 02453.
Is there a fee associated with this filing?
No, the filing indicates that no fee is required for this filing.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 4, 2025 regarding REPLIGEN CORP (RGEN).